The stock of Gilead Sciences Inc. (NASDAQ:GILD) traded at $67.20, down -0.05 percent on Monday. The last five days have seen an average of 4,248,542 shares of common stock traded. 22 times new highs were reached in the current year, with a gain of $8.96. The average number of shares traded over the last 20 days was 5,763,530, while the average volume over the last 50 days totaled 6,188,764.
GILD stock dropped -6.21% since last month. On 10/18/21, the company’s shares reached a one-month low of $65.78. The stock touched a high of $73.34 on 08/18/21, after rallying from a low of $56.56 in 52 weeks. The price of GILD stock has risen by 15.41% or $8.96 this year, reaching a new high 22 times. Still, the stock price is down -8.37% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 69 days since Gilead Sciences Inc. (GILD) last reported insider trading activity on Aug 17. On Aug 17, SVP, Controller & CAO Wilfong Diane E. sold 13,610 shares at $72.50 each. This transaction resulted in the insider making $986,725. On May 04, Mercier Johanna sold 19,496 shares at a price of US$66.09. After the transaction, the insider now owns 8,068 shares. Director Whitley Richard James had earlier sold 20,282 shares on May 03 for $64.57 a share. The transaction was completed for $1,309,655.
Gilead Sciences Inc. (GILD) has a trailing price-to-earnings (P/E) ratio of 16.50. This level actually compares favorably with the industry at large, as the PE for the Drug Manufacturers – General industry stands at about 27.24. Further, its PE also compares favorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.01 right now. The PE ratio of Gilead Sciences Inc. has varied between 855.75 and 6.599 in the last five years. Beta for the stock is 0.39. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.15, the price-to-book (PB) ratio of 4.28, and the price-to-cash flow ratio of 17.00.
Gilead Sciences Inc.’s dividend is $2.84 per share per year. With a dividend yield of 4.23%, GILD has a payout ratio of 67.60%. On Sep. 29, the company paid $0.71 per share in dividends, remained unchanged from $0.71 last year. A $0.03 dividend increase was reported on Thursday February 4 2021, making it the 6 consecutive year the dividend has increased. Over the last three years, dividends have increased by 30.77%.
For the three months ended June 29, Gilead Sciences Inc.’s quick ratio was 1.20, while its current ratio was 1.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.42, and the total debt to equity ratio is 1.53. As far as profitability goes, gross margin for the trailing twelve months is 80.10% percent. Gilead Sciences Inc.’s EBITDA margin for the year ended June 29 was 48.39%, whereas its operating margin stood at 36.70% for the same period. Based on annual data, it had gross profit of $20.12 billion and revenue of $24.69 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GILD’s return on assets (ROA) during the last 12 months has been 7.80%. There was a 5.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 27.80%. ROE has averaged -15.50 in the past year for the broader industry.
According to Gilead Sciences Inc.’s quarterly financial report for the quarter that ended June 29, it had $27.91 billion in total debt versus $1.63 billion in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.22 billion, while revenues rose by 17.28% to $6.42 billion. It was predicted that Gilead Sciences Inc.’s quarterly earnings would be $1.87, but it ended up being $1.73, beating the consensus by 8.10%. EBITDA was $2.77 billion for the quarter. At the end of Gilead Sciences Inc.’s most recent quarter ended June 29, its liabilities totaled 48.27 billion, while its total debt was $30.18 billion. Equity owned by shareholders amounts to $1.25 billion.
Here’s a quick look at Gilead Sciences Inc.’s (GILD) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 42.43%, suggesting the stock is Neutral, with a 17.13% historical volatility rate.
The stochastic %K and %D were 45.20% and 37.61% respectively, while the average true range (ATR) was 0.96. Based on the 14-day stochastic reading of 48.81%, the RSI (14) reading is 41.24%. On the 9-day MACD Oscillator, the stock is at -0.02, and the 14-day reading is at -0.25.
Analysts have assigned Gilead Sciences Inc. (GILD) an Overweight rating. GILD is a stock that is recommended for selling by 1 brokerage firm, while 14 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 9 others recommend it as a buy.
What is GILD’s price target for the next 12 months?
The current consensus forecast for the stock is between $63.00 and $100.00, with a median target price of $75.00. In analyzing these forecasts, the average price target given by analysts for Gilead Sciences Inc. (GILD) is $76.13.